×
About 183,640 results

ALLMedicine™ Prostate Cancer Center

Research & Reviews  84,327 results

Predictive value of the Spinal Instability Neoplastic Score for Survival and Ambulatory...
https://doi.org/10.1097/BRS.0000000000003835
Spine Wänman J, Jernberg J et. al.

Dec 4th, 2020 - We retrospectively analyzed Spinal Instability Neoplastic Score (SINS) in 110 patients with prostate cancer operated for metastatic spinal cord compression. We aimed to investigate the association between SINSs and clinical outcomes after surgery ...

Systematic Investigation of mRNA N 6-Methyladenosine Machinery in Primary Prostate Cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676945
Disease Markers; Jiang M, Lu Y et. al.

Dec 4th, 2020 - Appreciable findings have pointed out pivotal roles of N 6-methyladenosine (m6A) machinery in cancer onset and progression. However, limited efforts have been directed towards relevant research in the prostate cancer area. A PubMed search was cond...

Emerging Players in Prostate Cancer-Bone Niche Communication.
https://doi.org/10.1016/j.trecan.2020.09.006
Trends in Cancer; Furesi G, Rauner M et. al.

Dec 4th, 2020 - Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts ...

Revisiting prostate cancer metabolism: From metabolites to disease and therapy.
https://doi.org/10.1002/med.21766
Medicinal Research Reviews REFERENCES; Cardoso HJ, Carvalho TMA et. al.

Dec 4th, 2020 - Prostate cancer (PCa), one of the most commonly diagnosed cancers worldwide, still presents important unmet clinical needs concerning treatment. In the last years, the metabolic reprogramming and the specificities of tumor cells emerged as an exci...

Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of ...
https://doi.org/10.1038/s41391-020-00307-y
Prostate Cancer and Prostatic Diseases; Boeri L, Sharma V et. al.

Dec 3rd, 2020 - The optimal treatment for oligorecurrent prostate cancer (PCa) is a matter of debate. We aimed to assess oncologic outcomes of patients treated with metastasis-directed therapy (MDT) vs. androgen deprivation therapy (ADT) for oligorecurrent PCa. W...

see more →

Guidelines  377 results

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cance...
https://doi.org/10.1016/j.euf.2020.05.014
European Urology Focus; Siebert AL, Lapping-Carr L et. al.

Jul 21st, 2020 - Although substantial literature examining the neuropsychiatric consequences of androgen deprivation therapy (ADT) exists, there are no clinical guidelines to inform providers about the specific risk of depression, suicide, and dementia for prostat...

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achiev...

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
https://doi.org/10.1016/j.annonc.2020.06.011
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Parker C, Castro E et. al.

Jun 30th, 2020 - Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Parker C,Castro E,Fizazi K,Heidenreich A,Ost P,|

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/neal-shore-on-relugolix-vs-leuprolide-for-advanced-prostate-cancer/

May 31st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testoste...

see more →

Drugs  323 results see all →

Clinicaltrials.gov  91,969 results

Predictive value of the Spinal Instability Neoplastic Score for Survival and Ambulatory...
https://doi.org/10.1097/BRS.0000000000003835
Spine Wänman J, Jernberg J et. al.

Dec 4th, 2020 - We retrospectively analyzed Spinal Instability Neoplastic Score (SINS) in 110 patients with prostate cancer operated for metastatic spinal cord compression. We aimed to investigate the association between SINSs and clinical outcomes after surgery ...

Systematic Investigation of mRNA N 6-Methyladenosine Machinery in Primary Prostate Cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676945
Disease Markers; Jiang M, Lu Y et. al.

Dec 4th, 2020 - Appreciable findings have pointed out pivotal roles of N 6-methyladenosine (m6A) machinery in cancer onset and progression. However, limited efforts have been directed towards relevant research in the prostate cancer area. A PubMed search was cond...

Emerging Players in Prostate Cancer-Bone Niche Communication.
https://doi.org/10.1016/j.trecan.2020.09.006
Trends in Cancer; Furesi G, Rauner M et. al.

Dec 4th, 2020 - Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts ...

Revisiting prostate cancer metabolism: From metabolites to disease and therapy.
https://doi.org/10.1002/med.21766
Medicinal Research Reviews REFERENCES; Cardoso HJ, Carvalho TMA et. al.

Dec 4th, 2020 - Prostate cancer (PCa), one of the most commonly diagnosed cancers worldwide, still presents important unmet clinical needs concerning treatment. In the last years, the metabolic reprogramming and the specificities of tumor cells emerged as an exci...

Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of ...
https://doi.org/10.1038/s41391-020-00307-y
Prostate Cancer and Prostatic Diseases; Boeri L, Sharma V et. al.

Dec 3rd, 2020 - The optimal treatment for oligorecurrent prostate cancer (PCa) is a matter of debate. We aimed to assess oncologic outcomes of patients treated with metastasis-directed therapy (MDT) vs. androgen deprivation therapy (ADT) for oligorecurrent PCa. W...

see more →

News  6,475 results

FDA Approves First Agent for PSMA-PET Imaging in Prostate Cancer
https://www.medscape.com/viewarticle/941849

Dec 1st, 2020 - A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for institutional use at the University of California,...

Androgen-Deprivation Therapy Linked to Worse Fitness, CV Mortality
https://www.medscape.com/viewarticle/941819

Dec 1st, 2020 - NEW YORK (Reuters Health) - Long-term androgen-deprivation therapy (ADT) is associated with worse cardiorespiratory fitness (CRF) and higher cardiovascular (CV) mortality in prostate cancer (PC) patients with high CV risk at baseline, new research...

Fast Five Quiz: Castration-Resistant Prostate Cancer
https://reference.medscape.com/viewarticle/940541

Dec 1st, 2020 - As the fifth most common cause of cancer death in men worldwide, prostate cancer is largely identified in patients who are asymptomatic. For the most part, prostate cancer-related deaths occur as a result of advanced disease, which results from an...

Higher Risk of Falls/Fractures With Androgen Receptor Inhibitors
https://www.medscape.com/viewarticle/941793

Nov 30th, 2020 - An increase in the risk of falling and fracturing bones was associated with the use of androgen receptor inhibitors (ARIs) for the treatment of prostate cancer, a systematic review and meta-analysis suggests. "We know from this meta-analysis that ...

PSMA PET: A 'Real Game Changer' in High-Risk Prostate Cancer
https://www.staging.medscape.com/viewarticle/941238

Nov 17th, 2020 - Routinely collected clinical data help identify men with high-risk prostate cancer most likely to benefit from a gallium-68 prostate-specific membrane antigen (PSMA) PET/CT scan, according to a study reported at the American Society for Radiation ...

see more →

Patient Education  169 results see all →